Establishment and External Validation of a Hypoxia-Derived Gene Signature for Robustly Predicting Prognosis and Therapeutic Responses in Glioblastoma Multiforme.

Journal: BioMed research international
Published Date: Jan 1, 2022

Abstract

OBJECTIVE: Hypoxia presents a salient feature investigated in most solid tumors that holds key roles in cancer progression, including glioblastoma multiforme (GBM). Here, we aimed to construct a hypoxia-derived gene signature for identifying the high-risk GBM patients to guide adjuvant therapy and precision nursing based on signs of hypoxia.

Authors

  • Ke Wang
    China Electric Power Research Institute, Haidian District, Beijing 100192, China. wangke1@epri.sgcc.com.cn.
  • Yang Lu
    Spectral MD, Inc., 2515 McKinney Avenue, Suite 1000, Dallas, Texas 75201, United States.
  • Zhihong Liu
    National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
  • Min Diao
    Pediatric Intensive Care Unit, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, 271000 Shandong, China.
  • Lin Yang
    National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.

Keywords

External Resources

Popular Topics
Recent Journals